business activity

Our main profile is bacteriophage therapy. Bacteriophages (or shortly phages) are specific viruses that can infect only one bacterium species. Therefore, their effect is totally different from that of antibiotics, consequently they can be successfully applied in cases where antibiotics are not efficient.

The laboratory develops phage products attacking both human and plant pathogen bacteria. Our first phage-based marketed product is ERWIPHAGE, which combats Erwinia amylovora causing the fire-blight disease of apples. This product is the second phage-based pesticide in the world, but the first one against fire-blight. Due to the specific feature of phages, they do not destroy the soil improving useful bacteria. Since phages are harmless of human being, the products treated by ERWIPHAGE can be consumed without any delay. The pesticide has passed the test with its proved efficiency in a real life environment, too.

Among our activities, we also engage in the production and development of modern nanostructured materials.

1.) R&D projects:

Our R&D projects are classified into two gropus: bacteriophage therapy and other R&D projects.

Bacteriophage therapy:

Plant protection product against fire blight

Bacteriophages and their application in food safety

Building of Bacteriophage Therapy Center

Building of Nanophage Therapy Center

Development of plant production products based on phage therapy and nanotechnology